NEW YORK, NY / ACCESSWIRE / March 16, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Qudian Inc. (NYSE:QD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/qudian-inc-loss-submission-form?prid=5705&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: December 13, 2018 to January 15, 2020
Allegations against QD include that: (i) regulatory developments in China threatened to negatively impact Qudian’s fiscal full-year 2019 (“FY19”) financial results; (ii) Qudian’s business was unprepared to mitigate the risks associated with these regulatory changes; (iii) as a result, Qudian’s loan portfolio was plagued by growing delinquency rates; (iv) all of the foregoing made Qudian’s repeated assertions concerning its FY19 financial guidance unrealistic; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Geron Corporation (NASDAQ:GERN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5705&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018
The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
Becton Dickinson & Company (NYSE:BDX)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/becton-dickinson-company-loss-submission-form?prid=5705&wire=1
Lead Plaintiff Deadline: April 27, 2020
Class Period: November 5, 2019 to February 5, 2020
Allegations against BDX include that: (1) certain of Becton’s Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to “make enhancements;” (3) the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
To learn more, contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
Email: [email protected]
SOURCE: The Law Offices of Vincent Wong